

Index

A

- Acetyl-CoA carboxylase (ACC), 218
- Adenomatous polyposis coli (APC), 174
- AEH. *See* Atypical endometrial hyperplasia (AEH)
- AKT inhibitors, 160
- Aldo-keto reductase family (AKR1C), 10
- Aldo-keto reductase family 1, member C1 (AKR1C1), 11
- Aldo-keto reductase family 1, member C2 (AKR1C2), 11
- Aldo-keto reductase family 1, member C3 (AKR1C3), 11
- ALK. *See* Anaplastic lymphoma kinase (ALK)
- AMP-activated protein kinase (AMPK), 62, 218–220
- AMPK. *See* AMP-activated protein kinase (AMPK)
- Anaphase promoting complex (APC), 178
- Anaplastic lymphoma kinase (ALK), 171
- Atypical endometrial hyperplasia (AEH), 77
- Atypical polypoid adenomyoma (APAM), 83

B

- Bevacizumab, 68, 186
- β -Lactoglobulin promoter (*BLG-Cre*), 228
- Bone morphogenic proteins (BMPs), 180
- Brivanib, 186

C

- CAH. *See* Complex atypical hyperplasia (CAH)
- Cancer Genome Atlas, 103

Candidate genes

- FGFR2, 109–110
- KRAS, 108–109
- molecular defects, 110
- TP53, 104, 105
- Carboplatin and paclitaxel (CP), 67
- Catechol-*O*-methyltransferase (COMT), 11
- CDK inhibitors (CKIs), 177
- Cell cycle
 - APC, 178
 - AURKA siRNA, 180
 - CDK inhibitors, 179
 - cyclin A–CDK2, 178
 - cyclin D–CDK4/6, 177
 - cyclin E–CDK2, 178
 - cyclins and CDKs, 177
 - DP1 protein, 178
 - E2F polypeptide, 178
 - endometrial cancer, 178–179
 - eukaryotic cells, 177
 - MCM2–MCM7 complex, 178
- Chemotherapy, 67–68
- Cigarette smoking, 23–24
- Classification, EC
 - CTNNB1 mutations, 6
 - FOXA1 and HIF1, 7
 - genomic profile, 5
 - PARADIGM tumor clusters, 7
 - PR, 6
 - reverse-phase protein array data, 6
 - serous carcinomas, 5
 - TCGA, 5, 6
 - TP53 mutations, 6
 - type I and II, 5

c-Jun N-terminal kinases (JNK), 161, 175
 Clear cell carcinoma, 86
 Combined oral contraceptives (COCs), 18
 Complex atypical hyperplasia (CAH), 52, 53, 262
 Cowden syndrome, 79
 CREB-response elements (CRE), 224
 CREB-transcriptional coactivator (CRTC), 224
 Cystathionine- β -synthase (CBS), 219
 Cytochrome P450, family 1, subfamily B, polypeptide 1 (CYP1B1), 11
 Cytochrome P450, family 19, subfamily A, polypeptide 1 (CYP19A1), 10
 Cytochrome P450, family 3, subfamily A, polypeptide 7 (CYP3A7), 11

D

Diabetes, 21
 Disease-free survival (DFS), 60
 DNA microarray analysis, 244
 DNA mismatch repair (MMR)
 colon cancer, 102
 endometrial tumorigenesis
 and MLH1 epigenetic silencing, 102
 and MMR defects, 102
 epigenetic silencing, *MLH1*, 101
 germline mutations, 102
 IHC studies, 101
 methylation, 101
 MSH6, 102
 MSI, 101
 uterine cancers, 103
Drosophila, 221

E

4E binding protein 1 (4EBP1), 218
 EIN. *See* Endometrioid intraepithelial neoplasia (EIN)
 Endometrial cancer (EC)
 adjuvant chemotherapy
 EBRT/VBT, 60–62
 high-risk early-stage EC patients, 60, 61
 stages III–IV, 61–62
 adjuvant radiation therapy, 59–60
 bevacizumab, 186
 brivanib, 186
 chemotherapy, 67–68
 definitions, 58
 diagnosis, 49–50
 diagnostic dilemmas, 53
 epidemiology, 47–49
 Erlotinib, 185

fertility-sparing treatments, 63–64
 FIGO, 51
 Gefitinib, 185
 hormonal therapy, 67
 intermediate-risk patients, 58
 lapatinib, 185
 localized recurrence, 66
 lymphadenectomy, 56–57
 metformin, 185
 minimally invasive surgery, 56
 myometrial invasion, 58
 primary radiation therapy, 64
 primary treatment modalities, 62
 prognostic factors, 53–55
 ridaforolimus, 185
 surgical cytoreduction, 57
 surveillance, 64–66
 temsirolimus, 185
 trastuzumab, 185
 type I vs. II endometrial adenocarcinoma, 51–53
 Endometrial carcinoma (EC)
 adiponectin, 27
 adipose tissue, 26
 AEH/EIN, 77
 aggressive tumor types, 76
 AKT Inhibitors, 160
 aromatase, 25
 atrophic/inactive endometrium, 77
 BMI, 26
 case–control study, 25
 classification, 5–7
 clear cell, 78, 86
 clinical approach, 90–91
 colorectal, 79
 Cowden syndrome, 79
 cyclin E1, 79
 endometrioid adenocarcinoma, 79
 epidemiologic evidence, 26
 epidemiologic studies, 25
 ESR1 and PGR mutations, 12
 estrogen-producing tumor, 77
 factors, 25
 female reproductive organs, 76
 FIGO, 80
 glandular structures, 79
 grading, 89
 histopathological classification, 76
 immunohistochemistry, ER and PR, 83
 incidence and mortality rates, 4
 inflammation, 26
 insulin resistance, 26
 LVSI and MELF, 80
 Lynch syndrome, 79

- mixed, 87
 - mTOR inhibitors, 159–160
 - mucinous, 83
 - myometrial invasion, 80
 - neuroendocrine tumors, 88–89
 - obesity, 14
 - PI3K/AKT/mTOR, 154–155
 - inhibitors, 160–161
 - signaling pathway, 151–161
 - PI3KCA mutations, 153–154
 - PI3K inhibitors, 155–159
 - prognostic factors, 90
 - proliferative/hyperplastic endometrium, 77
 - PTEN inactivation, 152–153
 - PTEN knockout mouse models, 13–14
 - risk factors, 14–25
 - secretory variant differentiation, 81
 - serous carcinoma, 84–85
 - serum profiling, 27
 - somatic copy number alterations and aneuploidy, 78
 - squamous differentiation, 81
 - staging, 89–90
 - stromal cells, 83
 - TP53 mutations, 78
 - type I and II, 77, 78, 150
 - undifferentiation, 87–88
 - uterine cancer, 2
 - variant with secretory differentiation, 81
 - villoglandular variant, 81
 - visfatin, 27
 - Endometrial intraepithelial carcinoma (EIC), 52
 - Endometrioid endometrial adenocarcinomas (EEC), 52
 - Endometrioid intraepithelial neoplasia (EIN), 77
 - EPHR. *See* Ephrin receptors (EPHR)
 - Ephrin receptors (EPHR), 173
 - Epidermal growth factor (EGF), 244
 - Epithelial growth factor (EGF), 161
 - ERBB receptor feedback inhibitor 1 (ERRFI1), 244
 - Estrogen, 252
 - BMI, 8
 - CYP19A1*, 10
 - dysregulated expression, 10
 - endometrial cells, 7
 - endometrial tumor tissues, 8–12
 - epidemiologic studies, 8
 - HSD17B1, 11
 - HSD17B4 and HSD17B8 expressions, 11
 - HSD3B1, 10
 - low-grade tumors vs. high-grade tumors, 10
 - oncogenes and tumor suppressor genes, 7
 - peripheral tissues, 10
 - secretory phase, 8
 - sex steroid hormones, 7
 - SHBG, 8
 - STS, 10
 - Estrogen receptor- α (ER- α), 225
 - Estrogen responsive elements (EREs), 225
 - Express estrogen (ER), 77
 - External beam radiation therapy (EBRT), 58
 - Extracellular matrix (ECM), 233
 - Extracellular-signal-regulated kinases (ERK), 161
- F**
- Federation of Gynecology and Obstetrics (FIGO), 50
 - FGFR. *See* Fibroblast growth factor receptor (FGFR)
 - Fibroblast growth factor (FGF), 172
 - Fibroblast growth factor receptor (FGFR), 109
 - Fibroblast growth factor receptor (FGFR2), 5
 - Focal adhesion kinase (FAK), 174
 - Forkhead box A1 (FOXA1), 7
- G**
- Gamma-activated sequence (GAS), 225
 - GEMMs. *See* Genetically engineered mouse models (GEMMs)
 - Genetically engineered mouse models (GEMMs), 212, 226–227
 - Genome-wide association study (GWAS), 24
 - Genomic landscape
 - BCOR, 136
 - cancer-associated missense mutations, 122
 - C-class tumors, 125
 - CHD4, 124
 - CTNNB1* mutations, 134, 135
 - EC exomes, 121
 - endometrioid ECs, 125
 - FBXW7 tumor suppressor protein, 122
 - hypermutated-MSI
 - ARID1A tumor suppressor gene, 133
 - ARID5B-PHF2 complex, 133
 - Atbfl, 133
 - CSDE1/UNR* encodes, 133
 - CTCF zinc finger protein, 131
 - endometrial cancer, 129
 - exome sequencing, 129
 - GIGYF2 (PARK11), 133
 - JAK1 frameshift mutations, 132
 - JAK1 kinase, 131
 - KRAS and FGFR2, 133
 - LIMCH1, 134

Genomic landscape (*cont.*)

- NKAP transcriptional repressor, 134
- PTEN, PIK3CA and PIK3R1, 132
- RBMX, 134
- RNF43* E3 ubiquitin ligase, 131
- RPL22, 129, 131
- TCGA, 129
- WNT/ β -catenin pathway, 131
- ZFHX3/ATBF1, 133
- KRAS* and *FGFR2*, 135
- METTL14* mutations, 136
- pan-cancer analysis, 125
- PIKCA-PIK3R1-PTEN and ARID1A alterations, 134
- POLE* mutations, 126–128
- serous vs. endometrioid, 121
- SOX17* mutations, 134, 135
- SPOP, 122
- TAF1, 125
- TransPORTEC consortium, 127
- ultramutated phenotype, 126
- GTPase-activating proteins (GAP), 161
- Guanidine exchange factor (GEF), 161
- Gynecologic Oncology Group 33 (GOG-33), 53

H

- Hepatocyte growth factor ligand (HGF), 172
- Hereditary non-polypous colorectal cancer (HNPCC), 79
- HMG-CoA reductase (HMGR), 218
- Hormonal therapy, 67
- Human Genome Project, 120
- Hydroxysteroid (17-beta) dehydrogenase 1 (HSD17B1), 11
- Hydroxysteroid (17-beta) dehydrogenase 2 (HSD17B2), 12
- Hydroxysteroid (17-beta) dehydrogenase 7 (HSD17B7), 11
- Hydroxysteroid (17-beta) dehydrogenase 12 (HSD17B12), 11
- Hypoxia-inducible factor 1 (HIF1), 7

I

- IL-1 receptor antagonist (IL-1RA), 26
- Insulin growth factor 1 receptor (IGF-1R), 171
- Insulin growth factor-2 (IGF-2), 171
- International Agency on Cancer Research (IARC), 17
- International Cancer Genome Consortium, 120
- Intraoperative RT (IORT), 66
- Intrauterine devices (IUDs), 18

J

- Janus kinase family, 174

L

- Lapatinib, 185
- Large cell neuroendocrine carcinoma (LCNEC), 89
- Laser-capture microdissection (LCMD), 226
- LCNEC. *See* Large cell neuroendocrine carcinoma (LCNEC)
- LEGH. *See* Lobular endocervical glandular hyperplasia (LEGH)
- Liposomal doxorubicin, 68
- Liver kinase B1 (LKB1)
 - AMPK, 218–220
 - cell polarity and cancer, 221–222
 - CREB-dependent transcription, 224–225
 - endometrial adenocarcinoma mouse models, 212
 - epithelial vs. mesenchymal compartments, 213
 - epithelial tumor suppressor, 213
 - gastrointestinal tract, 213
 - germline/somatic mutations, 212
 - growth and tumor-promoting phenotypes, 212
 - gynecologic cancers, 213
 - hematopoiesis, 213
 - LEGH, 215
 - LKB1-AMPK-mTOR pathway, 222, 223
 - mammalian cells, 217–218
 - MDAs, 215
 - MLPA, 216
 - mouse models
 - Ad-Cre approach, 232
 - bona fide tumor suppressor, 229
 - cell-autonomous tumor suppressor, 229
 - cervical cancer, 234
 - Cre* transgene, 228
 - endometrial tumor suppressor, 229
 - endometrium, 228
 - epithelial pseudostratification, 229
 - GEMMs, 227
 - hypophosphorylation, 229
 - invasive and lethal cancers, 228
 - 17 *LKB1*^{+/+} homozygous, 229
 - MISR2*-Cre, 233
 - polyps and gastrointestinal carcinomas, 228
 - PTEN/LKB1 endometrial cancer model, 232
 - SCTAT/granulosa cell tumors, 234
 - Spr2f-Cre*, 230, 231

- stromal cells, 233
 - tumorigenic and nontumorigenic phenotypes, 228
 - uterine neoplasia, 234
 - nonepithelial malignancies, 212
 - phosphorylation, 218
 - regulation, cell polarity, 221
 - SCTAT, 215
 - serous cystadenomas and ovarian carcinomas, 216
 - specter, 216
 - spectrum, 216
 - transcriptional regulation, 225–226
 - translational studies, 212
 - Lobular endocervical glandular hyperplasia (LEGH), 215
 - Loss of heterozygosity (LOH), 104
 - Lymph vascular space involvement (LVSI), 80
 - Lymphadenectomy, 56–57
 - Lymphoid enhancer family (LEF), 175
 - Lynch syndrome, 48, 50, 79, 102
 - Lysyl oxidase (LOX), 223
- M**
- Madin–Darby canine kidney (MDCK), 221
 - Mammalian target of rapamycin (mTOR), 62
 - MAPK. *See* Mitogen-activated protein kinases (MAPK)
 - Mesenchymal epithelial transition factor (MET), 172
 - Metabolic equivalent of task (MET), 20
 - Metabolic syndrome, 21
 - Metformin, 185
 - Microsatellite instability (MSI), 5, 101, 120
 - Microsatellite stable (MSS), 101
 - Microtubule associated proteins (MAPs), 178
 - Minimal deviation adenocarcinoma (MDA), 214, 215
 - Minimally invasive surgery, 56
 - Mitogen-activated protein kinases (MAPK), 161
 - Mitogen-inducible gene 6 (*MIG-6*)
 - development, endometrial cancer, 247–248
 - endometrial stromal–epithelial communication, 248–250
 - endometrium, 246–247
 - ERK1/2 activity, 251–253
 - human endometrial cancer, 247
 - PRKO, 244
 - progesterone (P4), 243
 - protein–protein interaction domains, 244
 - and PTEN, 250–251
 - steroid hormone regulation, 246
 - tumor suppressor function, 245
 - Mixed malignant Mullerian tumor (MMMT), 87
 - MLPA. *See* Multiplex-ligation probe amplification (MLPA)
 - MMMT. *See* Mixed malignant Mullerian tumor (MMMT)
 - Molecular genetic analysis
 - DNA content studies, 100
 - endometrial cancer, 99
 - steroid hormone receptors, 103–104
 - Mouse mammary epithelial cells (MMECS), 222
 - MSI. *See* Microsatellite instability (MSI)
 - MSS. *See* Microsatellite stable (MSS)
 - mTOR inhibitors, 159
 - Mucinous carcinoma, 83
 - Multiplex-ligation probe amplification (MLPA), 216
 - Myeloproliferative neoplasms (MPNs), 174
- N**
- Next-generation sequencing
 - endometrial carcinosarcoma exomes, 121
 - germline mutations, 120
 - MSI, 120
 - Sanger sequencing, 120
 - somatic and germline mutations, 120
 - uterine cancers, 120
 - Nonreceptor tyrosine kinases (NRTKs)
 - cytoplasmic tyrosine kinase inhibitors, 173
 - FAK family, 174
 - JAK family, 174
 - SRC family, 173
 - Nonsmall cell lung carcinoma (NSCLC), 171, 223, 245
 - NSCLC. *See* Nonsmall cell lung carcinoma (NSCLC)
- P**
- PCOS. *See* Polycystic ovary syndrome (PCOS)
 - Pediatric Cancer Genome Project, 120
 - Peutz–Jeghers Syndrome (PJS), 212
 - Phosphatase and tensin homolog (PTEN)
 - AKT, 262
 - Cre/loxP sites, 267
 - Cre-lox system, 267
 - cribriform, 262
 - embryonic expression, 262
 - estrogen signaling, 269–271
 - germline knockout mice, 267
 - hematoxylin and eosin, 262

- Phosphatase and tensin homolog (PTEN) (*cont.*)
 immunohistochemistry, 263
 lipid phosphatase activity, 262
 luminal epithelium and glands, 262
 Mlh1, 263–266
 p-Akt immunostaining, 263
 protein kinase, 262
 uterine epithelium, 268–269
- PI3K inhibitors, 155–159
- PI3K/PTEN/AKT pathway
 Cre-Lox system, 262
 UEC, 261
- Piperidinoethoxyphenyl, 176
- Platelet-derived growth factor receptor
 (PDGF-R), 170, 171
- Polycystic ovary syndrome (PCOS), 23, 48
- Polymerase E (POLE), 78
- Progesterone (P4). *See* Estrogen
- Progesterone receptor (PGR), 77, 244
- Progesterone receptor knock-out mice
 (PRKO), 244
- Protein kinase C (PKC), 175
- PTEN gene
 endometrial cancers, 105
 endometrioid endometrial cancers, 106
 genomic region, 106
 LOH studies, 106
 MMR status, 106
 patient outcome, 107
 promoter methylation, 106
Pten +/- mouse model, 107
 tumor suppressors, 107
 tumorigenesis, 106
- R**
- RAS–RAF–MEK–ERK signaling pathway
 ERK and MAPKs, 161
 GAP and GEF, 161
in vitro neoplastic transformation, 164
 PI3K/AKT signaling pathway, 165
 PI3K/mTOR inhibitor, 165
 promoter hypermethylation, 164
 PTEN and K-RAS G12D mutation, 165
 RAF mutations, 163
 RAS mutations, 163
 TCGA, 164
- Receptor-associated late transducer
 (RALT), 244
- Receptor-regulated SMADs (R-SMADs), 180
- Receptor tyrosine kinases (RTKs), 160
- Restriction fragment length polymorphism
 (RFLP), 104
- Reverse phase protein array (RPPA), 253
- RFLP. *See* Restriction fragment length
 polymorphism (RFLP)
- Ridaforolimus, 185
- Risk factors, EC
 cigarette smoking, 23–24
 contraception methods, 18
 diabetes, 21
 etiologic heterogeneity, 25
 excess adiposity, 19–20
 family history, 24
 genetic risk, 24
 hormonal mechanisms, 14
 menarche and menopause, 22
 metabolic syndrome, 21
 non-contraceptive postmenopausal
 hormone, 14–17
 PCOS, 23
 physical activity, 20
 selective estrogen receptor modulators, 17
- S**
- Salt-inducible kinase (SIK), 224
- Sarcoma (SRC), 173
- Sarcomatous component (SC), 52
- SCNEC. *See* Small cell neuroendocrine
 carcinoma (SCNEC)
- SCTAT. *See* Sex cord tumor with annular
 tubules (SCTAT)
- SEIC. *See* Serous endometrial intraepithelial
 carcinoma (SEIC)
- Serine threonine kinase 11* (STK11), 211
- Serous carcinoma, 84–85
- Serous endometrial intraepithelial carcinoma
 (SEIC), 77
- Serum biomarkers, 65
- Sex cord tumor with annular tubules
 (SCTAT), 215
- Sex hormone-binding globulin (SHBG), 8
- Single-strand conformational variant
 (SSCV), 105
- Small cell neuroendocrine carcinoma
 (SCNEC), 88
- Small interfering RNA (siRNA), 245
- Snf-1 activating kinase-1 (Sak1), 219
- Sterile-20-related adaptor (STRAD), 217
- Steroid hormone receptors, 103–104
- Surveillance, epidemiology and end result
 (SEER), 63
- T**
- Tankyrase inhibitors, 177
- T-cell factor (TCF), 175

- The Cancer Genome Atlas (TCGA), 78, 120, 164
- The Tumor Cancer Genome Atlas (TCGA), 5
- Transforming growth factor alpha (TGF- α), 244
- Transforming growth factor β (TGF- β)
- epithelial cells, 180
 - I-SMADs, 181
 - isoforms, 180, 182–183
 - phosphorylated T β RI, 180
 - receptors, 183
 - R-SMADs, 180
 - signaling inhibitors, 184
 - SMAD proteins, 180, 183–184
 - transmembrane serine/threonine kinase receptor, 180
 - tumor suppressor, 180
- Trastuzumab, 185
- Tumor necrosis factor (TNF), 26
- Tumor suppressor complex 1 (TSC1), 218
- Tyrosine kinase inhibitor (TKI) therapy, 171–172
- Tyrosine kinases (TKs)
- clinical trials, 166–168
 - EGFR family, 166–169
 - EPH family, 173
 - FGFR family, 172
 - MET family, 172
 - nonreceptor, 166
 - PDGFR family, 170–171
 - protein kinases, 165
- RTKs, 166
- signaling molecules, 166
 - tumor progression, 166
 - VEGFR family, 169–170
- U**
- UDP glucuronosyltransferase 1 family, polypeptide A3 (UGT1A3), 11
- UEC. *See* Uterine endometrial carcinoma (UEC)
- Uterine clear cell (UCC), 52
- Uterine endometrial carcinoma (UEC), 261
- Uterine serous carcinoma (USC), 52
- V**
- Vascular endothelial growth factor (VEGF), 169
- W**
- WNT/ β -catenin signaling pathway
- Axin and GSK-3 β , 175
 - β -catenin/Armadillo, 174
 - cellular processes, 174
 - cyclin D1, C-MYC and MMP-7, 175
 - E-cadherin, 174
 - endometrial cancer, 175–176
 - hypophosphorylated β -catenin, 175
 - preclinical studies, 176–177